ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2947

Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus

Seiko Kondo-Ishikawa1, Takao Fujii2, Nozomi Ishigooka1, Kosaku Murakami1, Ran Nakashima1, Yoshitaka Imura1, Motomu Hashimoto2, Naoichiro Yukawa1, Hajime Yoshifuji1, Koichiro Ohmura1 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, chemokines and cytokines, IL-6, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoantibodies (auto Abs) in cerebrospinal fluid (CSF) and inflammatory mediators (IMs) may be involved in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE). Previous studies revealed that auto Abs such as anti-NMDA(N-methyl D-aspartate) receptor NR2 subunit (NR2) Abs are linked to a certain kind of NPSLE. We reported the association between NPSLE and CSF-anti-U1RNP Abs. What kinds of IMs in the central nervous system are stimulated by these Abs, however, remains unknown. The aim of the present study is to determine the association of both Abs with neurotoxic IMs.

Methods: Serum and CSF samples were obtained from NPSLE patients with diffuse NPSLE (n=39) or focal NPSLE (n=35), and non-NPSLE patients (control, n=13). Serum- and CSF-anti-NR2 Abs were determined by ELISA. Serum- and CSF-anti-U1RNP Ab positivity and titer were determined by RNA-immunoprecipitation assay and ELISA, respectively. CSF-IL-6, IL-8, and monokine induced by IFN-γ(MIG), which were reported to be neurotoxic, were measured by quantitative multiplex cytokine analysis. To elucidate the possibility that these IMs pass through blood-brain barrier (BBB), the permeability of BBB was evaluated by albumin quotient (Qalb).

Results: 1) IL-6 (67.4 vs. 17.5 pg/mL, p=0.02) and MIG (4307 vs. 109 pg/mL, p=0.03) levels, but not IL-8, were higher in CSF-anti-NR2 Ab-positive patients than controls. IL-6 level was higher in serum-anti-NR2 Ab-positive patients than in controls (50.0 vs. 17.4 pg/mL, p=0.03). There was no association of CSF-IMs with serum- and CSF-anti-NR2 Ab titer. CSF-anti-NR2 Ab positivity and titers were correlated with an increased permeability of BBB, as previously reported. 2) MIG level, but not IL-6 or IL-8, was higher in CSF-anti-U1RNP Ab-positive patients than in controls (2142 vs. 109 pg/mL, p=0.04). CSF-IMs were not correlated with serum-anti-U1RNP Ab titer. MIG level tended to positively correlated with CSF-anti-U1RNP Ab titer (r=0.49, p=0.07). 3) All the NPSLE patients were divided into 4 groups: CSF-anti-NR2 Ab +/U1RNP+ (double positive [DP], n=7), anti-NR2 Ab+/U1RNP- (NR2, n=18), anti-NR2-/U1RNP+ (U1RNP, n=9), anti-NR2 Ab-/U1RNP- (double negative [DN], n=40). In CSF-DP group, IL-6 and MIG levels, but not IL-8, were higher than in NR2 and U1RNP groups. 4) Qalb was positively correlated with IL-8 (r=0.45, p<0.0001) and MIG (r=0.56, p<0.0001) levels. Elevated CSF-IL-6 level, however, was not associated with an increased permeability of BBB. 5) The frequency of diffuse NPSLE in CSF-DP group (71%) tended to be higher than in the other groups. Auto Ab positivity was not associated with the brain MRI abnormalities.

Conclusion: CSF-IL-6 level was closely associated with the presence of CSF-anti-NR2 Abs, but not correlated with the BBB permeability. CSF-MIG level was associated with the presence of CSF-auto Abs and the BBB permeability. CSF-IL-8 level might be dependent of the BBB permeability alone. Thus, the involvements of auto Abs in CSF and BBB permeability in neurotoxic IM activation of NPSLE patients are different one another. The present study also suggests that NPSLE with both anti-NR2 and U1RNP Abs in CSF may have more severe manifestations.


Disclosure: S. Kondo-Ishikawa, None; T. Fujii, None; N. Ishigooka, None; K. Murakami, None; R. Nakashima, None; Y. Imura, None; M. Hashimoto, None; N. Yukawa, None; H. Yoshifuji, None; K. Ohmura, None; T. Mimori, None.

To cite this abstract in AMA style:

Kondo-Ishikawa S, Fujii T, Ishigooka N, Murakami K, Nakashima R, Imura Y, Hashimoto M, Yukawa N, Yoshifuji H, Ohmura K, Mimori T. Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/association-of-anti-nr2-and-u1rnp-antibodies-with-neurotoxic-inflammatory-mediators-in-cerebrospinal-fluid-from-patients-with-neuropsychiatric-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-anti-nr2-and-u1rnp-antibodies-with-neurotoxic-inflammatory-mediators-in-cerebrospinal-fluid-from-patients-with-neuropsychiatric-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology